search
Type 2 diabetes
Trends
- 1New tool predicts readmission risk in type 2 diabetes patients●A nomogram incorporating nutritional risk for predicting 31-day unplanned readmission in adults with type 2 diabetes mellitus using LASSO regression
Researchers have developed a nomogram that combines nutritional risk screening with LASSO regression to predict the likelihood of unplanned hospital readmission within 31 days for adults with type 2 diabetes. The tool, published in Frontiers, is intended to help clinicians identify high-risk patients early and target follow-up care, with nutritional status highlighted as a key predictive factor.
- 2Oral GLP-1 drug safiglipron shows promise in early type 2 diabetes trial●Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial
A randomized, double-blind, placebo-controlled trial published in Nature reports that safigliptron, an oral small-molecule GLP-1 receptor agonist, was tested in people with early type 2 diabetes. The publication is drawing attention as GLP-1 drugs reshape diabetes and obesity treatment, and an oral small-molecule option could be easier to take than injectable alternatives. Details on efficacy and safety are being reviewed by clinicians and researchers.
- 3Retatrutide Shows Record Weight Loss in Type 2 Diabetes Trial●Triple Agonist Retatrutide Pushes Weight Loss to New Levels in Type 2 Diabetes
Eli Lilly's triple agonist retatrutide has been reported to push weight loss to new levels among patients with type 2 diabetes, according to Inside Precision Medicine. The drug, which targets three hormone receptors, is being studied as one of the most powerful obesity and diabetes treatments in development, extending gains seen with tirzepatide and semaglutide.